Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcadia Biosciences (RKDA) Cash from Financing Activities (2016 - 2025)

Arcadia Biosciences filings provide 12 years of Cash from Financing Activities readings, the most recent being $1000.0 for Q3 2025.

  • On a quarterly basis, Cash from Financing Activities fell 75.0% to $1000.0 in Q3 2025 year-over-year; TTM through Dec 2025 was $6000.0, a 33.33% decrease, with the full-year FY2025 number at $6000.0, down 33.33% from a year prior.
  • Cash from Financing Activities hit $1000.0 in Q3 2025 for Arcadia Biosciences, down from $5000.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $22.0 million in Q1 2021 to a low of -$114000.0 in Q4 2021.
  • Median Cash from Financing Activities over the past 5 years was $5000.0 (2024), compared with a mean of $2.7 million.
  • Biggest five-year swings in Cash from Financing Activities: tumbled 101.47% in 2021 and later surged 137525.0% in 2023.
  • Arcadia Biosciences' Cash from Financing Activities stood at -$114000.0 in 2021, then surged by 4060.53% to $4.5 million in 2022, then tumbled by 99.84% to $7000.0 in 2023, then crashed by 42.86% to $4000.0 in 2024, then crashed by 75.0% to $1000.0 in 2025.
  • The last three reported values for Cash from Financing Activities were $1000.0 (Q3 2025), $5000.0 (Q1 2025), and $4000.0 (Q3 2024) per Business Quant data.